Tech Company Financing Transactions

Maze Therapeutics Funding Round

Arch Venture Partners, Third Rock Ventures and Alexandria Venture Investments participated in a $191 million funding round for Maze Therapeutics. The round was recorded on 3/1/2019.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

131 Oyster Point Blvd. 200
San Francisco, CA 94080
USA

Phone

Undisclosed

Website

www.mazetx.com

Email Address

[email protected]

Overview

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Charles Homcy

        

President

Jason Coloma

        

Vice President

Timothy Behrens

        

Vice President

Matthew Brauer

        

Vice President

David Morgans

        

VP - Bus. Development

Tara Nickerson

        

VP - R & D

Eric Green

        

Browse more venture capital transactions:

Prev: 3/1/2019: Beanfields venture capital transaction
Next: 3/1/2019: ThunderCore venture capital transaction

Share this article

About Our VC Transactions Data

We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary